<p>Eisai and Biogen presented five-year results from the CLARITY-AD long-term extension at the 19th Clinical Trials on Alzheimer’s Disease conference in Boston. The post Five-year data show continued benefits of lecanemab in early Alzheimer&#8217;s appeared first on Longevity.Technology.</p>